VYNE Therapeutics Inc. Stock price

Equities

VYNE

US92941V3087

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-02-27 pm EST 5-day change 1st Jan Change
2.37 USD +0.85% Intraday chart for VYNE Therapeutics Inc. +6.28% +1.72%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 * 500K Sales 2024 * 250K Capitalization 33.08M
Net income 2023 * -28M Net income 2024 * -33M EV / Sales 2023 * 66.2 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 132 x
P/E ratio 2023 *
-0.31 x
P/E ratio 2024 *
-1.13 x
Employees 12
Yield 2023 *
-
Yield 2024 *
-
Free-Float 86.2%
More Fundamentals * Assessed data
Dynamic Chart
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo CI
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000 MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : VYNE Therapeutics Inc. - Special Call
VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting MT
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday MT
Top Premarket Gainers MT
VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo CI
VYNE Therapeutics Inc. announced that it expects to receive $88.151509 million in funding CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $135,000 MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating MT
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news

Latest transcript on VYNE Therapeutics Inc.

1 day+0.85%
1 week+6.28%
Current month+38.60%
1 month+30.94%
3 months-40.30%
6 months-47.10%
Current year+1.72%
More quotes
1 week
2.10
Extreme 2.1
2.40
1 month
1.67
Extreme 1.67
2.40
Current year
1.67
Extreme 1.67
2.51
1 year
1.67
Extreme 1.67
8.73
3 years
1.67
Extreme 1.67
143.46
5 years
1.67
Extreme 1.67
291.60
10 years
1.67
Extreme 1.67
291.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 20-02-29
Director of Finance/CFO 38 -
Chief Tech/Sci/R&D Officer 51 20-02-29
Members of the board TitleAgeSince
Director/Board Member 69 20-09-09
Director/Board Member 59 14-12-31
Director/Board Member 68 20-02-29
More insiders
Date Price Change Volume
24-02-27 2.37 +0.85% 143,049
24-02-26 2.35 +3.98% 106,872
24-02-23 2.26 +4.15% 81,386
24-02-22 2.17 0.00% 38,304
24-02-21 2.17 -2.69% 36,171

Delayed Quote Nasdaq, February 27, 2024 at 04:00 pm EST

More quotes
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. Its FMX114 is investigational combination gel formulation of tofacitinib and fingolimod that is designed to address both the source and cause of inflammation in atopic dermatitis (AD). The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.37 USD
Average target price
5.583 USD
Spread / Average Target
+135.58%
Consensus
  1. Stock
  2. Equities
  3. Stock VYNE Therapeutics Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW